US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

54.29 +0.67 (+1.25%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TG Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
The Quest to Repair What Multiple Sclerosis Takes Away
Via Investor Brand Network
News headline image
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
From BioMedWire
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Via Investor Brand Network
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
From BioMedWire
Via GlobeNewswire
News headline image
The Most Shorted Stocks in June: Hold, Short, or Squeeze?
Given the proper catalyst, the short interest in these stocks may lead to a short squeeze. All the market needs is a push and it may come at any time. 
Via MarketBeat
News headline image
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
From FN Media Group LLC
Via GlobeNewswire
News headline image
TG Therapeutics Stock 300% Rally Has Legs Yet
There's further upside in the region of 30% yet to be realized, which should be more than enough to get even the more risk averse investor interested. 
Via MarketBeat
News headline image
TG Therapeutics, Inc. (NASDAQ:TGTX) Long Term Investor Alert: Investigation of Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 11/03/2022 -- Certain directors of TG Therapeutics, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
News headline image
Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds TG Therapeutics, Inc. (TGTX) Investors of Class Action and Last Few Hours to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
TG THERAPEUTICS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
TGTX FRIDAY DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages TG Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important September 16 Deadline in Securities Class Action - TGTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages TG Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TGTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
NASDAQ:TGTX Investor Alert: Lawsuit Alleges Securities Laws Violations by TG Therapeutics, Inc. ↗
San Diego, CA -- (SBWIRE) -- 08/17/2022 -- An investor, who purchased shares of TG Therapeutics, Inc. (NASDAQ:TGTX), filed a lawsuit in the over alleged violations of Federal Securities Laws by TG... 
Via SBWire
News headline image
TOP RANKED ROSEN LAW FIRM Encourages TG Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - TGTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
ROSEN, A LEADING LAW FIRM, Encourages TG Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - TGTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
TGTX Shareholder News: Robbins LLP is Investigating TG Therapeutics, Inc. (TGTX) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
News headline image
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages TG Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - TGTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Bronstein, Gewirtz & Grossman, LLC Notifies TG Therapeutics, Inc. (TGTX) Investors of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
ROSEN, A LEADING LAW FIRM, Encourages TG Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TGTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
TGTX Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against TG Therapeutics, Inc. (TGTX)
From Robbins LLP
Via Business Wire
News headline image
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against TG Therapeutics, Inc. (TGTX)
From Robbins LLP
Via Business Wire
News headline image
TG THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against TG Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
INVESTOR ACTON ALERT: The Schall Law Firm Encourages Investors in TG Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
SHAREHOLDER ACTON NOTICE: The Schall Law Firm Encourages Investors in TG Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
EQUITY ALERT: Rosen Law Firm Encourages TG Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – TGTX
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
TG Therapeutics, Inc. (NASDAQ:TGTX) Investor Alert: Investigation over Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 03/23/2022 -- Certain directors of TG Therapeutics, Inc are under investigation over potential breaches of fiduciary duties. 
Via SBWire
< Previous 1 2 Next >